Monoclonal antibody SP-2 to the tumour-associated antigen 90K was generated by immunisation with conditioned medium of human breast cancer cells. We investigated whether circulating levels of 90K can influence the prognosis of patients with breast cancer. Serum samples were obtained from 425 patients with histologically proven breast cancer with no clinical evidence of disease after surgery (NED) and in 310 patients with metastatic disease. Serum 90K was determined by a new immunoradiometric assay (IRMA). Antigen levels in NED patients were elevated in 18.5% of cases, mean levels being higher than in healthy controls (P = 0.001). Among 375 evaluable patients, the 75-month overall survival for 90K-negative (< or = 11 U ml-1) and 90K-positive (> 11 U ml-1) patients was 78% and 53% respectively (P = 0.004). The prognostic value of 90K appeared to be limited to patients with node-positive disease. Number of metastatic axillary lymph nodes and level of 90K antigen were the only independent variables for predicting overall survival. Patients with metastatic breast cancer had elevated 90K in 51.3% of cases. High 90K levels were significantly associated with the presence of metastases to liver, shorter disease-free interval and younger age. We conclude that an elevated 90K antigen level in serum is a predictor of poor prognosis in breast cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968766 | PMC |
| http://dx.doi.org/10.1038/bjc.1994.29 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Potential and development of cellular vesicle vaccines in cancer immunotherapy.
Discov Oncol
January 2025
Department of Breast Surgery, The First Affiliated Hospital of Harbin Medical University, No. 23, Youzheng Street, Nangang District, Harbin, 150001, China.
Cancer vaccines are promising as an effective means of stimulating the immune system to clear tumors as well as to establish immune surveillance. In this paper, we discuss the main platforms and current status of cancer vaccines and propose a new cancer vaccine platform, the cytosolic vesicle vaccine. This vaccine has a unique structure that can integrate antigen and adjuvant carriers to improve the delivery efficiency and immune activation ability, which brings new ideas for cancer vaccine design.
View Article and Find Full Text PDFMachine learning-based prognostic modeling and surgical value analysis of de novo metastatic invasive ductal carcinoma of the breast.
Updates Surg
January 2025
Department of Radiation Oncology, The First Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
Whether primary lesion surgery improves survival in patients with de novo metastatic breast cancer (dnMBC) is inconclusive. We aimed to establish a prognostic prediction model for patients with de novo metastatic breast invasive ductal carcinoma (dnMBIDC) based on machine learning algorithms and to investigate the value of primary site surgery. The data used in our study were obtained from the Surveillance, Epidemiology, and End Results database (SEER, 2010-2021) and the First Affiliated Hospital of Nanchang University (1st-NCUH, June 2013-June 2023).
View Article and Find Full Text PDFRole of Acorus calamus extract in reducing exosome secretion by targeting Rab27a and nSMase2: a therapeutic approach for breast cancer.
Mol Biol Rep
January 2025
Kusuma School of Biological Sciences, Indian Institute of Technology Delhi, Hauz Khas, New Delhi, 110016, India.
Background: Exosomes are extracellular vesicles released by cells that mediate intercellular communication and actively participate in cancer progression, metastasis, and regulation of immune response within the tumour microenvironment. Inhibiting exosome release from cancer cells could be employed as a therapeutic against cancer.
Methods And Results: In the present study, we have studied the effects of Acorus calamus in inhibiting exosome secretion via targetting Rab27a and neutral sphingomyelinase 2 (nSMase2) in HER2-positive (MDA-MB-453), hormone receptor-positive (MCF-7) and triple-negative breast cancer (MDA-MB-231) cells.
Revolutionizing radiotherapy: gold nanoparticles with polyphenol coating as novel enhancers in breast cancer cells-an in vitro study.
Discov Nano
January 2025
Department of Mathematics and Physics "Ennio De Giorgi", University of Salento, Via Arnesano, 73100, Lecce, LE, Italy.
Breast cancer is the most common cancer among women, with over 1 million new cases and around 400,000 deaths annually worldwide. This makes it a significant and costly global health challenge. Standard treatments like chemotherapy and radiotherapy, often used after mastectomy, show varying effectiveness based on the cancer subtype.
View Article and Find Full Text PDFAttention-guided erasing for enhanced transfer learning in breast abnormality classification.
Int J Comput Assist Radiol Surg
January 2025
Pattern Recognition Lab, Friedrich-Alexander-University Erlangen-Nuremberg, Martensstr. 3, 91058, Erlangen, Bayern, Germany.
Purpose: Breast cancer remains one of the most prevalent cancers globally, necessitating effective early screening and diagnosis. This study investigates the effectiveness and generalizability of our recently proposed data augmentation technique, attention-guided erasing (AGE), across various transfer learning classification tasks for breast abnormality classification in mammography.
Methods: AGE utilizes attention head visualizations from DINO self-supervised pretraining to weakly localize regions of interest (ROI) in images.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!